In Australia, there are many health care providers including, the medical professionals, allied health workers, general practitioners and nurses. Australian health care market is mixed consisting of private as well as public systems. The public system comprises of public hospitals, community-based services, and affiliated health organisations governed by the state. The private system comprises health service providers which are owned and managed privately such as private hospitals, allied health workers, pharmacies and medical specialist. Australian health care system is facing few challenges which include- ageing population, chronic disease, new technology and advances made in medical research.
In this article we are discussing five ASX listed health care stocks-
Fisher & Paykel Healthcare Corporation Limited (ASX: FPH)
An ASX listed health care player Fisher & Paykel Healthcare Corporation Limited (ASX: FPH) is a provides products which are used in respiratory care and is a leader in the marketing, manufacturing and designing of these systems and products.
Recently on 27 November 2019, the company updated the market with the half-year results for FY2020 (half year ended 30 September 2019). The key highlights are-
- The operating revenue of the company was NZ$570.9 million, up by 12% as compared to the prior corresponding year.
- The company reported 24% growth in NPAT to a record NZ$121.2 million.
- FPH recorded 19% growth in operating revenue (Hospitals), 17% growth in constant currency.
- A constant currency revenue growth reported as- 23% for new applications consumables.
- The company recorded Homecare operating revenue growth - 2%.
- In OSA masks, 1% decline is recorded in constant currency revenue.
- The R&D investment was 9% (NZ$54 million) of revenue.
The company’s stock settled the day at $20.470 on 28 November 2019 up by 1.086%, with a market capitalisation of $11.63 billion. With nearly 574.39 million outstanding shares, the stock has a 52 weeks high price of $20.450 and a 52 weeks low price of $11.280.
Sonic Healthcare Limited (ASX: SHL)
Sydney headquartered global healthcare company Sonic Healthcare Limited (ASX: SHL) offers pathology, laboratory and imaging services to health care practitioners and hospitals. The company is the third-largest pathology/laboratory medicine company across the globe by achieving excellent growth.
Sonic Healthcare Limited recently reported its annual general meeting (AGM) presentation highlighting the performance in the FY2019 (year ended 30 June 2019)-
The company generated an increased revenue of 11.6% worth $6.2 billion for FY2019 as compared to the prior corresponding period (pcp).
- The EBITDA of the company was reported to increase by 13.3% worth $1.1 billion, as compared to pcp.
- The underlying EBITDA growth (constant currency) for the FY2019 was at 6.7%.
- Sonic recorded net profit growth of $550 million for FY2019.
- The company acquired aurora Diagnostics in January 2019.
Outlook- Sonic Healthcare Limited expects more growth opportunities in the upcoming years by the geographical diversification made in the fiscal year 2019 and the company also has well-planned pipeline contract opportunities, acquisitions and joint ventures.
The SHL’s stock settled the day at $30.310 on 28 November 2019 down by 0.915%, with a market capitalisation of $14.53 billion. The stock has delivered a positive return of 40.32% on the year to date basis.
Cochlear Limited (ASX: COH)
An ASX listed medical device company Cochlear Limited (ASX: COH) is into development and supply of implantable hearing solutions to provide a lifetime of hearing outcomes. Currently, the company is operating through the segments spanning across Americas, EMEA and the Asia Pacific regions and sells its products in more than 100 countries.
Cochlear™ Osia® 2 System approval-
Cochlear announced to have a secured Food and Drug Administration (FDA) approval for its Cochlear™ Osia® 2 System which is the world’s first active osseointegrated steady-state implant. Osia® 2 System is approved in the United States for 12 years and older adults and children having single-sided sensorineural deafness and conductive or mixed hearing loss. Cochlear also disclosed that it would commence commercialisation of Osia® 2 System during the second half of the financial year 2020, in the United States.
The company’s stock was traded at $233.730 on 28 November 2019 up by 1.1645%, with a market capitalisation of $13.36 billion. With approximately 57.83 million outstanding shares, the stock has a 52 weeks high price of $235.710 and a 52 weeks low price of $164.000.
Ansell Limited (ASX: ANN)
A world-leading superior health and safety protection provider Ansell Limited (ASX: ANN) is into improving human well-being. The company is continuously working on the development of product innovation and technology. Ansell is operating in two primary business segments which are healthcare and industrial. The company employs over 12,000 people globally. With more than 100 customers, Ansell operates in Latin America/Caribbean, Asia Pacific, North America, and EMEA.
Key highlights FY2019- (year ended 30 June 2019)
- Ansell generated a Sales revenue of US$1,499.0 million in the fiscal year 2019.
- The company reported an EBIT of US$202.8 million.
- The Operating Cash Flow of the company recorded at US$164.7 million.
- The company reported a net cash inflow of US$188.9 million from operating activities.
- With strong sales growth coming from synthetic surgical products, Ansell’s surgical and healthcare safety solutions grew by 3.4%.
- Life Sciences products continued to grow strongly by 11.1% supported by the recent acquisitions of gammaSUPPLIES and Nitritex.
Five-year performance history Source: Annual report
The company’s stock settled the day at $29.730 on 28 November 2019 up by 0.168 %, with a market capitalisation of $3.88 billion. The stock has delivered a positive return of 35.77% on the YTD basis. The P/E ratio of the company stands at 25.220x, with an Annual dividend yield of 2.27%.
EBOS Group Limited (ASX: EBO)
Health care leading player EBOS Group Limited (ASX: EBO) is the largest and most diversified marketer and distributor of health care products. The company employs more than 3,600 employees and sells its products in 58 locations in Australia.
Sale of EBOS shares -
Sybos Holdings Pte Ltd (Sybos) would sell 15,000,000 of its shares in EBO Group Limited to the investors (invited to attend the bookbuild) and has signed an underwriting deal with a financial institution. According to this agreement, the sale of the shares being conducted by a fixed price bookbuild.
It is expected that the sold shares are to be widely held by investors, and Sybos is expected to decrease its shareholding in the EBOS group.
The company’s stock was traded at $22.070 on 28 November 2019 up by 2.651%. The stock has a market cap of approximately $3.49 billion, with approximately 162.12 million outstanding shares. The stock has a 52 weeks high price and a 52 weeks low price of $24.500 and $18.750 respectively.
This website is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The website has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. Kalkine Media does not in any way endorse or recommend individuals, products or services that may be discussed on this site. Our publications are NOT a solicitation or recommendation to buy, sell or hold. We are neither licensed nor qualified to provide investment advice.
There is no investor left unperturbed with the ongoing trade conflicts between US-China and the devastating bushfire in Australia.
Are you wondering if the year 2020 might not have taken the right start? Dividend stocks could be the answer to that question.
As interest rates in Australia are already at record low levels, find out which dividend stocks are viewed as the most attractive investment opportunity in the current scenario in our report.